Arrowhead to Present at Upcoming Investor Conferences

PASADENA, Calif.–(BUSINESS WIRE)–

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical

company developing targeted RNAi therapeutics, today announced that it

will present at two upcoming investor conferences.

Scheduled presentations include the following:

Wells Fargo 2014 Healthcare Conference – Boston

June 17, 2014 – At 1:45 p.m. EDT Christopher Anzalone, Ph.D.,

President and Chief Executive Officer, will deliver a corporate

presentation, and at 2:20 p.m. EDT he will participate in the “Gene

Manipulation” panel discussion

Piper Jaffray GenomeRx Symposium – New York

June 23, 2014 – At 3:30 p.m. EDT David Lewis, Ph.D., Chief

Scientific Officer, will participate in the “RNA/DNA: Getting It Where

You Need It” panel discussion

About Arrowhead Research Corporation

Arrowhead Research Corporation is a biopharmaceutical company developing

targeted RNAi therapeutics. The company is leveraging its proprietary

drug delivery technologies to develop targeted drugs based on the RNA

interference mechanism that efficiently silences disease-causing genes.

Arrowhead technologies also enable partners to create peptide-drug

conjugates that specifically home to cell types of interest while

sparing off-target tissues. Arrowhead’s pipeline includes clinical

programs in chronic hepatitis B virus and partner-based programs in

obesity and oncology.

For more information please visit http://www.arrowheadresearch.com,

or follow us on Twitter @ArrowRes.

To be added to the Company’s email list to receive news directly, please

send an email to ir@arrowres.com.

Arrowhead Research Corporation
Vince Anzalone, CFA
626-304-3400
ir@arrowres.com
or
Investor

Relations:
The Trout Group
Lauren Glaser
646-378-2972
ir@arrowres.com
or
Media:
Russo

Partners
Martina Schwarzkopf, Ph.D.
212-845-4292
martina.schwarzkopf@russopartnersllc.com

Source: Arrowhead Research Corporation

News Provided by Acquire Media